TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular CarcinomaSummary

TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular CarcinomaSummary

Background & Aims: TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer immunotherapy in HCC is unknown. PD1 blockade is clinically effective in about 20% of advanced HCC patients. Here we aim to determine whether co-blockade of TIGIT/PD1 has added value to restore f...

Full description

Bibliographic Details
Main Authors: Zhouhong Ge, Guoying Zhou, Lucia Campos Carrascosa, Erik Gausvik, Patrick P.C. Boor, Lisanne Noordam, Michael Doukas, Wojciech G. Polak, Türkan Terkivatan, Qiuwei Pan, R. Bart Takkenberg, Joanne Verheij, Joris I. Erdmann, Jan N.M. IJzermans, Maikel P. Peppelenbosch, Jaco Kraan, Jaap Kwekkeboom, Dave Sprengers
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Cellular and Molecular Gastroenterology and Hepatology
Subjects:
TIGIT
CD226
TOX
HCC
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352345X21000552

Internet

http://www.sciencedirect.com/science/article/pii/S2352345X21000552

Similar Items